Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

s risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

 



'/>"/>
SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... September 18, 2014 Leatherwood Plastics ... listed material, to stay competitive in the semiconductor, ... high-performance materials ultimately impact product quality and productivity, ... owner. , Established in 1980 in Lewisville, TX, ... many fabricators have left the business. Much of ...
Breaking Biology Technology:Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... (Nasdaq: PBIO ) ("PBI" or the "Company") today ... was $334,041 compared to $174,071 for the comparable period in ... PCT products and services was $233,256 for the three months ... period in 2007, a 97% increase. During the fourth ...
... 4 Tigris Pharmaceuticals, Inc., a privately held ... New Drug (IND) application for the Company,s geranylgeranyltransferase ... Food and Drug Administration. This will allow the ... the safety of GGTI-2418 during the first quarter ...
... Head of Nektar Therapeutic,s Pulmonary Business Unit, Among ... Savara, Inc., a biopharmaceutical company developing novel ... today announced that it has expanded its Board ... Elam, former head of the pulmonary business unit ...
Cached Biology Technology:Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Savara Expands Board of Directors, Appoints Three New Members 2Savara Expands Board of Directors, Appoints Three New Members 3
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
(Date:9/18/2014)... are too stressed they are often grouchy, grumpy, nasty, ... (BMI) at EPFL have just highlighted a fundamental synaptic ... the loss of social skills and cognitive impairment. When ... molecule in the brain. This was revealed by a ... Carmen Sandi,s team went to look for answers in ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Greenhouse gas research enters a new era 2How stress tears us apart 2
... looking good for him. Up until now he has been in ... he finishes first is often decided by just a few seconds. ... on the cross-country ski run, the condition of the athlete on ... Olympic skiing stars who are wooed by sponsors, up until now ...
... that celiac disease is increasing in prevalence because farmers are ... conclusion of an article in the ACS, Journal of ... evidence that the incidence of celiac disease increased during the ... the disease is 4 times more common today. Also known ...
... Michael Pogue, a Research Entomologist in the ARS ... , Washington, DC, was sent a series of moth ... under consideration as a possible biocontrol agent for the ... species was initially identified as a common species, but ...
Cached Biology News:Optimized custom-made ski sledges 2Optimized custom-made ski sledges 3Biocontrol research on Brazilian peppertree in Florida discovers new cryptic species 2